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1. INTRODUCTION {#cam42921-sec-0005}
===============

Hepatocellular carcinoma has been recognized as the fifth most common primary malignant tumor and the second leading cause of cancer‐related deaths globally.[1](#cam42921-bib-0001){ref-type="ref"} The main risk factor for tumorigenesis is chronic viral hepatitis, alcoholic liver disease, diabetes and nonalcoholic steatohepatitis (NASH).[2](#cam42921-bib-0002){ref-type="ref"} The outcome of HCC is poor: according to the Surveillance, Epidemiology, and End Results (SEER) database, the 5‐year survival rate of local hepatocellular carcinoma patients is 30.5%, and the rate is less than 5% for patients with distant metastasis.[3](#cam42921-bib-0003){ref-type="ref"} Although partial hepatectomy and liver transplantation are the main treatment methods for early‐stage patients, few patients are eligible for these treatments, and approximately 70% of patients will relapse within five years after surgery.[4](#cam42921-bib-0004){ref-type="ref"} Moreover, it is generally observed that HCC is not very sensitive to radiation and chemotherapy. To date, sorafenib and lenvatinib have been approved as targeted therapies for hepatocellular carcinoma by the United States Food and Drug Administration (FDA) to treat unresectable HCC; however, they have limited effectiveness.

It had been shown that several components of the immune system were key factors during tumor development and progression. Recent studies also indicated that dysregulation of the immune system including alteration in the number or function of immune cells, the release of chemokine and cytokine, and expression of inhibitory receptors or their ligands can lead to the progression of hepatocellular carcinoma.[5](#cam42921-bib-0005){ref-type="ref"}, [6](#cam42921-bib-0006){ref-type="ref"} Moreover, immune checkpoint inhibitors that specifically target PD1/PD‐L1 had indicated a manageable safety and lasting response in advanced hepatocellular carcinoma.[7](#cam42921-bib-0007){ref-type="ref"} So far, there is no research which has constructed a prognosis signature by using immune‐related gene.

In this study, based on immune‐related genes from the ImmPort database, we used two RNA‐seq datasets from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) and one microarray dataset (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520>) to establish and validate a 33‐immune‐related gene pair signature for hepatocellular carcinoma patients. Then, we investigated the relationship between clinicalpathological factors and the prognostic signature. Finally, we compared this signature with other existing prognostic signatures to prove the predictive effectiveness and accuracy of this signature.

2. METHODS {#cam42921-sec-0006}
==========

2.1. Data source {#cam42921-sec-0007}
----------------

The level‐three RNA‐seq expression data and clinical data of 377 HCC patient samples were downloaded from the TCGA data portal (<https://portal.gdc.cancer.gov>); patients with an overall survival time less than one month were excluded, and the dataset was randomly split into a training dataset (n = 206) and a testing dataset (n = 106). Another RNA‐seq dataset (n = 207) was downloaded from ICGC, and a microarray dataset (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520>) downloaded from the GEO database (<http://www.ncbi.nlm.nih.gov/geo>) was used as a dataset for validation of the signature. We downloaded 1534 immune‐related genes from the ImmPort database (<https://immport.niaid.nih.gov>). The immune‐related genes included cytokines, cytokine receptors, and genes correlated with the T‐cell receptor and B‐cell antigen receptor signaling pathways, natural killer cell cytotoxicity, and the antigen processing and presentation pathways.

2.2. Data preprocessing {#cam42921-sec-0008}
-----------------------

When multiple probes matched the same target gene, the average expression value of the probes was used to represent the single gene expression level. When a patient had more than one sample, the average expression value of each gene was used to represent the level of gene expression in the patient.

2.3. Establishment of the prognostic signature based on immune‐related genes {#cam42921-sec-0009}
----------------------------------------------------------------------------

A pairwise comparison was performed between the immune‐related gene expression value in each sample to obtain a score for each IRGP. If the expression level of the first IRG was higher than that of the second IRG in a specific IRGP, the score of this IRGP was 1; otherwise, the score was 0. If the score of an IRGP was 0 or 1 in more than 90% of the samples of the TCGA training dataset or the TCGA testing dataset, then we discarded the IRGP. The log‐rank test was applied to select the prognostic IRGPs (FDR \< 0.01) in the training dataset, and then Lasso penalized Cox regression (iteration = 1000) was applied to generate a more stable prognostic gene model by using an R package (glmnet, version: 2.0‐16). The tuning parameter was estimated in the training dataset by performing 10‐fold cross‐validation. The most stable gene pair model was used to construct the prognostic signature, and then patients were assigned into high immune risk and low immune risk groups according to an immune risk cutoff score; the median value of the risk score was set as the cutoff value.

2.4. Validation and assessment of the IRGP signature {#cam42921-sec-0010}
----------------------------------------------------

To validate the IRGP signature, the risk score was calculated according to the prognostic signature in every testing dataset; then, we assigned patients into low immune risk and high immune risk groups according to the median value of the risk score. The overall survival difference between the low immune risk and high immune risk groups was evaluated by the log‐rank test and Cox regression analysis. In addition, we compared the prognostic signature with three existing gene prognostic signatures by the receiver operating characteristic curve (ROC) curve and c‐index analyses in the full TCGA dataset.

2.5. Gene set enrichment analysis {#cam42921-sec-0011}
---------------------------------

To understand the underlying biological mechanisms of this immune‐related prognostic signature, we performed gene set enrichment analysis by using the MSigDB hallmark gene set (<http://software.broadinstitute.org/gsea/downloads.jsp>). An FDR value below 0.25 was considered statistically significant.

2.6. Statistical analysis {#cam42921-sec-0012}
-------------------------

All statistical analyses were performed using GraphPad Prism 6 and R software (version 3.5.1, <https://www.r-project.org/>). The log‐rank test was used to evaluate the relationship between IRGPs and overall survival. The survival curves were generated by the R package "survminer". The gene model was conducted with the "glmnet" package. The ROC curves were conducted by an R package called "survivalROC". The c‐index was calculated by the R package "survcomp".

3. RESULTS {#cam42921-sec-0013}
==========

3.1. Construction and definition of the IRGP signature {#cam42921-sec-0014}
------------------------------------------------------

To make our investigation procedure clearer, the entire workflow is illustrated in Figure [1](#cam42921-fig-0001){ref-type="fig"}. As shown in Table [1](#cam42921-tbl-0001){ref-type="table"}, a total of 765 HCC patients were included in our study. The TCGA dataset was randomly split into a training dataset (n = 206) and a testing dataset (n = 136). A total of 822 immune‐related genes were common among all datasets, and 337 431 IRGPs were constructed. Ultimately, we kept 99 615 IRGPs after removing IRGPs with a score of 0 or 1 in more than 90% of the samples in the TCGA training or testing datasets. Using the log‐rank test, we selected 188 prognostic IRGPs that were significantly associated with patient overall survival (FDR \< 0.01). Next, the prognostic IRGPs were used to construct prognostic gene models by using Lasso penalized Cox regression on the TCGA training dataset. After 1000 iterations, the 33‐gene model, which had the highest frequency of (424) compared with the other nine gene models (Table [S1](#cam42921-sup-0002){ref-type="supplementary-material"}), was used to construct the prognostic signature (Figure [2](#cam42921-fig-0002){ref-type="fig"}A). The 33‐IRGP prognostic signature information is shown in Table [2](#cam42921-tbl-0002){ref-type="table"}. The 33 IRGPs could accurately predict patient prognosis in the training dataset (Figure [S1](#cam42921-sup-0001){ref-type="supplementary-material"}). The area under the receiver operating characteristic curve (AUC) values of the 1‐, 3‐, and 5‐year survival rates were 0.912, 0.918, and 0.816, respectively, in the training dataset (Figure [2](#cam42921-fig-0002){ref-type="fig"}D), which demonstrated that the predictive ability of our IRGP prognostic signature was promising. In the training dataset, the risk score of each patient was calculated with the immune prognostic signature, and then patients were assigned into low immune risk and high immune risk groups according to the median risk score. As shown in Figure [2](#cam42921-fig-0002){ref-type="fig"}C, the high immune risk group had a poorer prognosis than the low immune risk group (HR: 10.89, 95%CI: 8.09‐21.07, *P* \< .0001) in the training dataset. We also found consistent results in the subgroup analysis (Table [3](#cam42921-tbl-0003){ref-type="table"}, Figure [2](#cam42921-fig-0002){ref-type="fig"}).

![The workflow describes the construction and validation of our 33 IRGPs. The TCGA data were assigned into a training dataset (206) and a testing dataset (136), and the training dataset was used to construct immune‐related gene pair signatures. The testing, <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520> and ICGC datasets were used to validate the 33‐immune‐related gene pair signature](CAM4-9-2868-g001){#cam42921-fig-0001}

###### 

Clinical and pathologic factors of the datasets used in this study

                              TCGA (n, %)           ICGC (n, %)   <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520> (n, %)
  --------------------------- --------------------- ------------- ---------------------------------------------------------------------
  Age                                                             
  \<60                        66 (19.3%)            39 (19.3%)    178 (80.5%)
  ≥60                         276 (80.7%)           163 (80.7%)   43 (19.5%)
  Gender                                                          
  Female                      109 (31.9%)           50(24.8%)     30(13.6%)
  Male                        233 (68.1%)           152 (75.2%)   191 (86.4%)
  Virus infection                                                 
  Yes                         142(41.5%)            173 (85.7%)   212 (96%)
  No                          200(58.5%)            29 (14.3%)    6 (2.7%)
  NA                                                              3 (1.3%)
  Cirrhosis                                                       
  Yes                         127 (37%)             193(95.5%)    18(8.1%)
  No                          72 (21%)              9(4.5%)       203(91.9%)
  NA                          143 (42%)                            
  Recurrence                                                      
  Yes                         173 (50.6%)                         121 (54.8%)
  No                          125 (36.5%)                         100 (45.2%)
  NA                          44 (12.9%)                           
  TNM stage                                                       
  Stage I                     103                                 93 (42.1%)
  Stage II                    39                                  77 (34.8%)
  Stage III                   47                                  49 (22.2%)
  Stage IV                    2                                   2 (0.9%)
  NA                                                              0
  Survival status                                                 
  Alive                       219 (64.0%)           167 (82.7%)   136 (61.5%)
  Dead                        123 (36%)             35 (17.3%)    85 (38.5%)
  Median follow‐up time(mo)   20.745 (1.02‐120.7)   27 (1‐72)     52.3 (2‐67.4)

Abbreviations: ICGC, ICGC LIHC dataset; NA represents information not available; TCGA, TCGA LIHC dataset.

John Wiley & Sons, Ltd

![Construction and definition of IRGP signature. A, After 1000 iterations, the 33‐IRGP model achieved the highest frequency compared with the other nine IRGP models. The 33‐IRGP model was selected to construct the IRGP signature. B, The heatmap shows the score of the 33 IRGPs according to patient risk score. The patients were divided into high immune risk and low immune risk groups according to the median risk score. The red and black points represent the risk scores of high‐risk group patients and low‐risk group patients, respectively. The gray and green points represent patients who were alive or dead, respectively. C, The survival curve shows that high‐risk group patients had a poorer outcome than low‐risk group patients in the training dataset (*P* \< .05). D, Generation of receiver operating characteristic (ROC) curves illustrated the predictive ability of the 33‐immune‐related gene pair model. The areas under the curves for 1‐, 3‐, and 5‐year survival were 0.912, 0.918, and 0.814, respectively, in the training dataset](CAM4-9-2868-g002){#cam42921-fig-0002}

###### 

Information on the 33 IRGPs

  Gene pair1   Full name                                                                        Gene pair2   Full name                                                                                   Coefficient
  ------------ -------------------------------------------------------------------------------- ------------ ------------------------------------------------------------------------------------------- -------------
  ADM2         Adrenomedullin 2                                                                 GHR          Growth hormone receptor                                                                     0.094222
  AMHR2        Anti‐Mullerian hormone receptor, type II                                         OGN          Osteoglycin                                                                                 0.000652
  ARTN         Artemin                                                                          IFI30        Interferon, gamma‐inducible protein 30                                                      0.89792
  CALCR        Calcitonin receptor                                                              KLRK1        Killer cell lectin‐like receptor subfamily K, member 1                                      0.472908
  CALCR        Calcitonin receptor                                                              NTF3         Neurotrophin 3                                                                              0.110016
  CCR3         Chemokine (C‐C motif) receptor 3                                                 IGF1         Insulin‐like growth factor 1 (somatomedin C)                                                0.025693
  CCR3         Chemokine (C‐C motif) receptor 3                                                 NCR1         Natural cytotoxicity triggering receptor 1                                                  0.070971
  CD1A         CD1a molecule                                                                    FASLG        CD1a molecule                                                                               0.231429
  CD1C         CD1c molecule                                                                    SEMA3C       CD1c molecule                                                                               −0.32233
  CDK4         Cyclin‐dependent kinase 4                                                        PIK3R1       Cyclin‐dependent kinase 4                                                                   0.489564
  CHGA         Chromogranin A (parathyroid secretory protein 1)                                 PDCD1        Chromogranin A (parathyroid secretory protein 1)                                            0.483017
  CTSE         Cathepsin E                                                                      MPL          Cathepsin E                                                                                 0.152814
  CXCL1        Chemokine (C‐X‐C motif) ligand 1 (melanoma growth stimulating activity, alpha)   RELB         Chemokine (C‐X‐C motif) ligand 1 (melanoma growth stimulating activity, alpha)              0.082072
  CXCL5        Chemokine (C‐X‐C motif) ligand 5                                                 PDCD1        Programmed cell death 1                                                                     0.031422
  EDN1         Endothelin 1                                                                     SOS2         Son of sevenless homolog 2 (Drosophila)                                                     0.164111
  EDN1         Endothelin 1                                                                     TNFRSF10D    Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain   0.299299
  EPOR         Erythropoietin receptor                                                          PLXNA1       Plexin A1                                                                                   −0.11661
  FYN          FYN oncogene related to SRC, FGR, YES                                            STC1         Stanniocalcin 1                                                                             −0.37861
  GHR          Growth hormone receptor                                                          PLXNA2       Plexin A2                                                                                   −0.03843
  GIP          Gastric inhibitory polypeptide                                                   OGN          Osteoglycin                                                                                 0.227285
  GMFB         Glia maturation factor, beta                                                     PIK3R1       Phosphoinositide‐3‐kinase, regulatory subunit 1 (alpha)                                     0.003817
  GPR17        G protein‐coupled receptor 17                                                    IL5          Interleukin 5 (colony‐stimulating factor, eosinophil)                                       −0.14056
  HLA‐A        Major histocompatibility complex, class I, A                                     SPP1         Secreted phosphoprotein 1                                                                   −0.04005
  HLA‐DRB1     major histocompatibility complex, class II, DR beta 1                            SPP1         Secreted phosphoprotein 1                                                                   −0.14776
  IL15RA       Interleukin 15 receptor, alpha                                                   SHC2         SHC (Src homology 2 domain containing) transforming protein 2                               0.455341
  IL18RAP      Interleukin 18 receptor accessory protein                                        SEMA3A       Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A      −0.35545
  IL1RL1       Interleukin 1 receptor‐like 1                                                    MTNR1A       Melatonin receptor 1A                                                                       −0.56454
  IL5          Interleukin 5 (colony‐stimulating factor, eosinophil)                            OGN          Osteoglycin                                                                                 0.361037
  KIR2DS4‐                                                                                      PRKCG        Protein kinase C, gamma                                                                     −0.49709
  KITLG        KIT ligand                                                                       SH3BP2       SH3‐domain binding protein 2                                                                0.035557
  KITLG        KIT ligand                                                                       TGFBR3       Transforming growth factor, beta receptor III                                               0.107891
  LECT2        Leukocyte cell‐derived chemotaxin 2                                              NR6A1        Leukocyte cell‐derived chemotaxin 2                                                         −0.24611
  LTB4R2       Leukotriene B4 receptor 2                                                        SEMA3A       Leukotriene B4 receptor 2                                                                   −0.1266

John Wiley & Sons, Ltd

###### 

Clinical subgroup analysis of prognosis based on our IRGP signature

  Variable          No. of patients   HR(95%CI)   Log‐rank *P*‐value     
  ----------------- ----------------- ----------- ---------------------- ---------
  All               103               104         10.89 (8.09‐21.07)     \<.0001
  Age                                                                    
  Age \< 60         25                13          29.17 (10.05 −186.3)   \<.0001
  Age ≥ 60          78                90          8.99 (8.090 −21.07)    \<.0001
  Gender                                                                 
  Female            35                35          6.03 (4.243 −19.85)    \<.0001
  Male              68                68          19.95 (8.572 −28.92)   \<.0001
  TNM                                                                    
  StageI/Ⅱ          87                63          13.88 (12.29 −48.39)   \<.0001
  StageⅢ/Ⅳ          15                40          5.32 (1.947 −7.748)    .0002
  Grade                                                                  
  G1/G2             73                59          9.05 (8.245 −28.29)    \<.0001
  G3/G4             29                43          10.35 (4.637 −23.11)   \<.0001
  Viral infection                                                        
  No                52                70          8.44 (5.296 ‐ 15.38)   \<.0001
  Yes               51                33          14.40 (7.895 −59.81)   \<.0001
  Recurrence        46                62          7.19 (4.375 −13.85)    \<.0001

Abbreviations: All, TCGA LIHC dataset; CI, confidence interval; HR, hazard ratio.

John Wiley & Sons, Ltd

3.2. Validation of the IRGP signature {#cam42921-sec-0015}
-------------------------------------

In the TCGA, ICGC, and <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520> datasets, the risk score of each patient was calculated with the same 33‐IRGP prognostic signature, and patients were assigned into low immune risk and high immune risk groups according to the median risk score. The high immune risk group had poorer OS in all datasets than the low immune risk group (Figure [3](#cam42921-fig-0003){ref-type="fig"}A‐C). The c‐index values for the training, testing, ICGC and <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520> datasets were 0.78, 0.62, 0.61, and 0.59, respectively (Figure [3](#cam42921-fig-0003){ref-type="fig"}D). The multivariate Cox regression analysis showed that the IRGP risk score was an independent prognostic factor after adjustment for by age, sex, and TNM stage in the training (HR: 20.59, 95%CI: 8.73‐48.54, *P* = .000), testing (HR: 2.07, 95%CI: 1.07‐4.015, *P* = .031), <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520> (HR: 1.77, 95%CI: 1.09‐2.87) and ICGC datasets (HR: 2.40, 95%CI: 1.19‐4.82).

![Validation of the IRGP signature. As shown, patients with a high risk score have a worse overall survival rate than those in the low risk score group according to Kaplan--Meier survival analysis in the TCGA test dataset (A), <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14529> dataset (B), and ICGC dataset (C). These results show that the 33‐IRGP model has a robust predictive ability (*P* \< .05). D: The c‐index values for the training dataset, testing dataset, <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520> dataset, and ICGC dataset were 0.78, 0.62, 0.59, and 0.61, respectively](CAM4-9-2868-g003){#cam42921-fig-0003}

3.3. COMPARISON WITH OTHER PUBLISHED PROGNOSTIC SIGNATURES {#cam42921-sec-0016}
----------------------------------------------------------

We also compared our IRGP prognostic signature with three published gene prognostic signatures[8](#cam42921-bib-0008){ref-type="ref"}, [9](#cam42921-bib-0009){ref-type="ref"}, [10](#cam42921-bib-0010){ref-type="ref"} by constructing an ROC curve for 5‐year OS and determining the c‐index, and all data came from TCGA. As shown in Figure [4](#cam42921-fig-0004){ref-type="fig"}A‐B and Table [4](#cam42921-tbl-0004){ref-type="table"}, the AUC was 0.772 and the c‐index was 0.717 for our prognostic signature, and the IRGP prognostic signature possessed a higher predictive efficacy and accuracy than the existing three‐gene prognostic signature (AUC = 0.691, c‐index = 0.641), the 4‐gene prognostic signature (AUC = 0.702, c‐index = 0.674) and the autophagy‐related signature (AUC = 0.408, c‐index = 0.600) (Table [5](#cam42921-tbl-0005){ref-type="table"}).

![Determination of the receiver operating characteristic (ROC) curve (A) and c‐index (B) for different prognostic signatures. The AUC values for the IRGP model, three‐gene model, four prognostic lncRNA model, and autophagy‐related signature were 0.772, 0.691, 0.702, and 0.408, respectively. The c‐index values for the IRGP model, three‐gene model, four prognostic lncRNA model, and autophagy‐related signature were 0.772, 0.691, 0.702, and 0.408, respectively. These results indicate that our signature possesses a higher predictive efficacy and accuracy than the other models](CAM4-9-2868-g004){#cam42921-fig-0004}

###### 

Multivariate Cox analysis of clinicopathological factors and risk signatures

  Variable                                                               HR      95%CI        *P*‐value
  ---------------------------------------------------------------------- ------- ------------ -----------
  Training dataset                                                                            
  Risk_score (low risk vs high risk)                                     20.59   8.73‐48.54   .000
  Age (\<60 vs ≥60)                                                      1.17    0.58‐2.36    .662
  Stage (I and II vs III and IV)                                         1.77    1.06‐2.97    .029
  Gender (male vs female)                                                1.16    0.70‐1.91    .574
  Testing dataset                                                                             
  Risk_score                                                             2.07    1.07‐4.015   .031
  Age(\<60 vs ≥60)                                                       0.68    0.34‐1.38    .289
  Stage (I and II vs III and IV)                                         2.27    1.21‐4.23    .010
  Gender (male vs female)                                                1.61    0.859‐3.02   .138
  ICGC dataset                                                                                
  Risk_score                                                             2.40    1.19‐4.82    .014
  Age (\<60 vs ≥60)                                                      0.955   0.413‐2.21   .913
  Gender (male vs female)                                                0.481   0.24‐0.98    .045
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520> dataset                        
  Risk_score                                                             1.77    1.09‐2.87    .022
  Age (\<60 vs ≥60)                                                      1.05    0.58‐1.90    .868
  Stage (I and II vs III and IV)                                         2.78    1.71‐4.50    .00
  Gender (male vs female)                                                1.37    0.65‐2.87    .408

Abbreviations: CI, confidence interval; HR, hazard ratio.

John Wiley & Sons, Ltd

###### 

c‐index and AUC values between different signatures

  Signature                     AUC     c‐index
  ----------------------------- ------- ---------
  IRGPs                         0.772   0.717
  3 gene signature              0.691   0.641
  4 prognostic signature        0.702   0.674
  Autophagy‐related signature   0.408   0.600

Abbreviations: AUC, area under the receiver operating characteristic (ROC) curve; c‐index, concordance index.

John Wiley & Sons, Ltd

3.4. Biological processes correlated with the IRGP signature {#cam42921-sec-0017}
------------------------------------------------------------

We assigned patients into low immune risk groups and high immune risk groups, and gene set enrichment analysis (GSEA) was performed on the training dataset. The result illustrated that a total of nine cancer hallmark gene sets were identified in the high‐risk group (Figure [5](#cam42921-fig-0005){ref-type="fig"}) including "MYC_TARGETS," "GLYCOLYSIS," and "DNA_REPAIR," which indicated that these hallmark gene sets played a critical role in HCC progression.

![Gene set enrichment analysis (GSEA) between high and low immune risk groups. The results show that nine cancer hallmark gene sets are enriched in the high immune risk group in patients with HCC (*P* \< .05, FDR \< 0.25)](CAM4-9-2868-g005){#cam42921-fig-0005}

4. DISCUSSION {#cam42921-sec-0018}
=============

It is well‐known that the liver participates in self‐tolerance and contains the richest immune effectors in the body.[11](#cam42921-bib-0011){ref-type="ref"} Several components of the immune system, including immune cells, chemokines, cytokines, and inhibitory receptors and ligands, have been shown to be key factors during tumor development and progression.[5](#cam42921-bib-0005){ref-type="ref"}, [6](#cam42921-bib-0006){ref-type="ref"} The complex immune environment of the liver makes immunotherapy a promising yet complicated strategy for treatment. There has also been a rapid rise in the amount of immunotherapy clinical trials in HCC in the past 15 years.[12](#cam42921-bib-0012){ref-type="ref"}, [13](#cam42921-bib-0013){ref-type="ref"}, [14](#cam42921-bib-0014){ref-type="ref"} Among these trials, immune checkpoint (PD1/PDL1 and CTLA‐4) blockade therapy has received great acclaim. Nivolumab (anti‐PD1) was the first FDA‐approved immune checkpoint inhibitor for HCC. In phase I and phase II clinical trials, 20% of HCC patients treated with nivolumab had a lasting response. In addition, several clinical trials of immune checkpoint inhibitors have also shown exciting results. HCC, like many other tumors, has an immunosuppressive microenvironment that can inhibit the activation of immune effectors, making adoptive immunotherapy a promising method. Recently, adoptive immunotherapies, including CIK cells, NK cells, NKT cells and CAR T cells, accounted for approximately half of the immunotherapy clinical trials in HCC (12 trials), and several studies have reported that adoptive immunotherapy can delay recurrence and prolong survival time.[15](#cam42921-bib-0015){ref-type="ref"}, [16](#cam42921-bib-0016){ref-type="ref"}, [17](#cam42921-bib-0017){ref-type="ref"} Cancer vaccines are another immunotherapy that can help the immune system recognize and attack cancer cells. Unfortunately, current vaccine monotherapies do not generate significant clinical outcomes in patients with HCC.[18](#cam42921-bib-0018){ref-type="ref"} In summary, immunotherapy is a promising treatment approach in HCC, and the immunology of hepatocellular carcinoma needs to be further explored. So, it is necessary to construct a prognostic signal using immune‐related genes.

Traditional prognostic signatures require the preprocessing of gene expression profiles, and this is a major factor that influences other widely used models. In this study, because our IRGPs were generated by pairwise comparison and the score was calculated entirely based on gene expression in the same patient, our prognostic signature can not only overcome the batch effects of the different platforms but also does not require the scaling and normalization of data. This approach has been reported to be robust in several studies, including cancer‐related studies, and it is a major advantage in our study.[19](#cam42921-bib-0019){ref-type="ref"}, [20](#cam42921-bib-0020){ref-type="ref"}

In this study, by using Lasso penalized Cox regression, we constructed a 33‐IRGP prognostic signature and validated this signature in several different datasets. The results showed that our signature could stratify patients into high immune risk and low immune risk groups. Univariate and multivariate Cox proportional hazard regression analyses showed that the score was an independent prognostic factor. In our study, unlike in traditional studies, the signature was constructed by using Lasso penalized regression, which can identify the most suitable of many variables. Moreover, our signature was validated by several datasets, including RNA‐seq and microarray datasets. Finally, compared with the other three existing prognostic signatures, our signature possesses a higher predictive efficacy and accuracy.[8](#cam42921-bib-0008){ref-type="ref"}, [9](#cam42921-bib-0009){ref-type="ref"}, [10](#cam42921-bib-0010){ref-type="ref"}

Our 33‐IRGP signature consists of 54 immune‐related genes, and these genes are mainly involved in the functions of immune cells and antigen identification and presentation and they play an important role in the composition of the immune microenvironment. CXCL5 and CXCL1 can promote intratumoral neutrophil infiltration, and their overexpression has been correlated with poor prognosis in HCC.[21](#cam42921-bib-0021){ref-type="ref"}, [22](#cam42921-bib-0022){ref-type="ref"}, [23](#cam42921-bib-0023){ref-type="ref"} CDK4 is a promising anticancer target in several cancers, including hepatocellular carcinoma. Shom Goel et al recently found that CDK4/6 inhibitors could promote tumor immunogenicity and may have synergistic effects with immunotherapy.[24](#cam42921-bib-0024){ref-type="ref"}, [25](#cam42921-bib-0025){ref-type="ref"} It was reported that the downregulation of LECT2 fostered the accumulation of inflammatory monocytes, which harbor immunosuppressive properties, and promoted the progression of hepatocellular carcinoma.[26](#cam42921-bib-0026){ref-type="ref"} PD1 is mainly expressed on effector T cells in tumor tissues in HCC. Compared with cirrhotic tissue, tumor tissue has a higher number of PD‐1+CD8+ T cells. Moreover, patients with higher levels of tumor‐infiltrating and circulating PD‐1+CD8+ T cells tend to progress early after posthepatic resection.[27](#cam42921-bib-0027){ref-type="ref"} It has been reported that macrophages can be recruited into HCC tissue by SEMA3A, and overexpression of SEMA3A indicates poor prognosis in hepatocellular carcinoma.[28](#cam42921-bib-0028){ref-type="ref"} Artemin was shown to be related to early relapse, shortened overall survival and large tumor size.[29](#cam42921-bib-0029){ref-type="ref"} The involvement of all the above mentioned genes indicates that immune processes contribute to tumor development and prognosis. Other immune‐related genes in our signature can also predict the prognosis of HCC patients. In addition, expression imbalances in certain gene pairs may play a more important role than individual differentially expressed genes. GSEA indicated that "MYC_TARGETS," "DNA_REPAIR," and "GLYCOLYSIS" were enriched in the high‐risk group, and these results were consistent with previous reports.[30](#cam42921-bib-0030){ref-type="ref"}, [31](#cam42921-bib-0031){ref-type="ref"}, [32](#cam42921-bib-0032){ref-type="ref"}

Nevertheless, we should acknowledge the limitations of this study. First, our research was a retrospective analysis, and a prospective cohort is needed to validate the results. Second, because the signature was constructed by using immune‐related genes, our signature does not represent diverse biological processes. Finally, the signature was constructed by using RNA‐seq and microarray expression data. Further clinical applications should be evaluated by using RT‐PCR or IHC.

In conclusion, we developed a new IRGP prognostic model in HCC.
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